{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:50:19Z","timestamp":1792839019992,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1053\/j.semnuclmed.2019.06.010","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T17:11:51Z","timestamp":1562260311000},"page":"484-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["PET\/CT for Evaluation of Ovarian Cancer"],"prefix":"10.1053","volume":"49","author":[{"given":"Jukka","family":"Kemppainen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Virtanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0001","unstructured":"National Cancer Institute. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer Stat Facts: Ovarian Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0002","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0003","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00404-014-3364-8","article-title":"The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer","volume":"290","author":"Zeppernick","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bpobgyn.2005.10.007","article-title":"Worldwide burden of gynaecological cancer: The size of the problem","volume":"20","author":"Sankaranarayanan","year":"2006","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0005","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.291.22.2705","article-title":"Frequency of symptoms of ovarian cancer in women presenting to primary care clinics","volume":"291","author":"Goff","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0006","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1148\/radiology.197.3.7480729","article-title":"Ovarian cancer: Staging with CT and MR imaging","volume":"197","author":"Forstner","year":"1995","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0007","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s00259-006-0260-x","article-title":"Role of [18F]FDG PET\/CT in the assessment of suspected recurrent ovarian cancer: Correlation with clinical or histological findings","volume":"34","author":"Chung","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2009.10.003","article-title":"Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review","volume":"75","author":"Pentheroudakis","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0009","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2214\/ajr.183.6.01831721","article-title":"CT features of serous surface papillary carcinoma of the ovary","volume":"183","author":"Kim","year":"2004","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.maturitas.2009.09.009","article-title":"Managing hereditary ovarian cancer","volume":"64","author":"Mourits","year":"2009","journal-title":"Maturitas"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0011","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0090-8258(91)90099-Q","article-title":"Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer","volume":"40","author":"Burghardt","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/IGC.0b013e3181cf6271","article-title":"Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer","volume":"20","author":"Nomura","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0013","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ygyno.2007.01.028","article-title":"Pelvic and aortic lymph node metastasis in epithelial ovarian cancer","volume":"105","author":"Pereira","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0014","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1200\/JCO.2002.20.4.982","article-title":"Epithelial ovarian cancer metastasizing to the brain: A late manifestation of the disease with an increasing incidence","volume":"20","author":"Kolomainen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4143\/crt.2012.44.2.142","article-title":"Metastatic skin lesions on lower extremities in a patient with recurrent serous papillary ovarian carcinoma: A case report and literature review","volume":"44","author":"Kim","year":"2012","journal-title":"Cancer Res Treat"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0016","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1093\/annonc\/mdt398","article-title":"Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube","volume":"24","author":"Sehouli","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0017","series-title":"Clinicical Gynecologic Ongology: Epithelial Ovarian Cancer","author":"DiSaia","year":"2012"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0018","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0019","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/AOG.0000000000000917","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"126","author":"Prat","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0021","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: A gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0022","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0023","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/MNM.0000000000000091","article-title":"Management of epithelial ovarian cancer from diagnosis to restaging: An overview of the role of imaging techniques with particular regard to the contribution of 18F-FDG PET\/CT","volume":"35","author":"Musto","year":"2014","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0024","first-page":"266","article-title":"Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: Assessment by PET\/CT","volume":"45","author":"Lerman","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0025","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1148\/rg.254045155","article-title":"Imaging of pelvic malignancies with in-line FDG PET-CT: Case examples and common pitfalls of FDG PET","volume":"25","author":"Subhas","year":"2005","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2214\/ajr.177.1.1770123","article-title":"Preoperative diagnosis of ovarian tumors with MR imaging: Comparison with transvaginal sonography, positron emission tomography, and histologic findings","volume":"177","author":"Rieber","year":"2001","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0027","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00259-005-1771-6","article-title":"Incidental ovarian 18F-FDG accumulation on PET: Correlation with the menstrual cycle","volume":"32","author":"Kim","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0028","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1006\/gyno.1994.1345","article-title":"Preoperative evaluation of patients with suspected ovarian cancer","volume":"55","author":"Brooks","year":"1994","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0029","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/IGC.0000000000000074","article-title":"ATL","volume":"24","author":"Tanizaki","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrclinonc.2010.47","article-title":"Imaging ovarian cancer and peritoneal metastases\u2014Current and emerging techniques","volume":"7","author":"Kyriazi","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0031","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2006.11.022","article-title":"The diagnostic value of PET\/CT for primary ovarian cancer\u2014A prospective study","volume":"105","author":"Risum","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0032","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MNM.0b013e3281afa256","article-title":"Diagnostic accuracy of 18F-FDG PET\/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology","volume":"28","author":"Castellucci","year":"2007","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijgo.2008.02.019","article-title":"Preoperative evaluation of pelvic masses with combined 18 F-fluorodeoxyglucose positron emission tomography and computed tomography","volume":"102","author":"Yamamoto","year":"2008","journal-title":"Int J Gynecol Obstet"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0034","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2009.10.059","article-title":"Diagnosis and staging of primary ovarian cancer: Correlation between PET\/CT, Doppler US, and CT or MRI","volume":"116","author":"Nam","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0035","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ygyno.2013.08.020","article-title":"PET\/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer","volume":"131","author":"Dauwen","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0036","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.ejrad.2016.08.006","article-title":"Use of 18 F-FDG PET\/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue","volume":"85","author":"Lopez-Lopez","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0037","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2013.08.023","article-title":"A prospective comparison of integrated FDG-PET\/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer","volume":"131","author":"Hynninen","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0038","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.ejrad.2010.07.013","article-title":"FDG-PET\/CT in advanced ovarian cancer staging: Value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy","volume":"80","author":"De Iaco","year":"2011","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0039","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12149-010-0449-8","article-title":"Present and future of FDG-PET\/CT in ovarian cancer","volume":"25","author":"Kitajima","year":"2011","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0040","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.ejrad.2011.01.112","article-title":"Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography\/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: A meta-analysis","volume":"81","author":"Yuan","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0041","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00330-013-3083-8","article-title":"Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: A clinical feasibility study in comparison to CT and FDG-PET\/CT","volume":"24","author":"Michielsen","year":"2014","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0042","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.ygyno.2013.09.024","article-title":"Preoperative 18F-FDG PET\/CT in the management of advanced epithelial ovarian cancer","volume":"131","author":"Fruscio","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0043","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ygyno.2009.12.008","article-title":"Does the use of diagnostic PET\/CT cause stage migration in patients with primary advanced ovarian cancer","volume":"116","author":"Risum","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0044","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00259-011-1984-9","article-title":"Prognostic significance of mediastinal 18F-FDG uptake in PET\/CT in advanced ovarian cancer","volume":"39","author":"Bats","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2012.04.023","article-title":"FDG PET\/CT in staging of advanced epithelial ovarian cancer: Frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread","volume":"126","author":"Hynninen","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0046","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1186\/s12885-018-5067-1","article-title":"Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18F-FDG PET\/CT in advanced epithelial ovarian cancer","volume":"18","author":"Lee","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0047","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0048","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2012.05.014","article-title":"Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer","volume":"126","author":"Chang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0049","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0051","first-page":"150","article-title":"Targeted therapy for ovarian cancer: The rapidly evolving landscape of PARP inhibitor use","volume":"70","author":"Walsh","year":"2018","journal-title":"Minerva Ginecol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0052","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ygyno.2019.02.020","article-title":"Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)\/NRG oncology clinical trials of the past twenty years","volume":"153","author":"DiSilvestro","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0053","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3802\/jgo.2012.23.1.28","article-title":"Preoperative [18 F]FDG PET\/CT predicts recurrence in patients with epithelial ovarian cancer","volume":"23","author":"Chung","year":"2012","journal-title":"J Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0054","first-page":"53","article-title":"The pretreatment of maximum standardized uptake values (SUVmax) of the primary tumor is predictor for poor prognosis for patients with epithelial ovarian cancer","volume":"66","author":"Nakamura","year":"2012","journal-title":"Acta Med Okayama"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3109\/0284186X.2010.500296","article-title":"Standardized FDG uptake as a prognostic variable and as a predictor of incomplete cytoreduction in primary advanced ovarian cancer","volume":"50","author":"Risum","year":"2011","journal-title":"Acta Oncol (Madr)"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0056","doi-asserted-by":"crossref","first-page":"7445","DOI":"10.1200\/JCO.2005.06.965","article-title":"Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer","volume":"23","author":"Avril","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0057","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2015.10.018","article-title":"18F-FDG-PET\/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"140","author":"Vallius","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0058","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-018-3961-z","article-title":"18F-FDG-PET\/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer","volume":"45","author":"Vallius","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0059","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1007\/s00259-014-2803-x","article-title":"The role of metabolic tumor volume and total lesion glycolysis on 18F-FDG PET\/CT in the prognosis of epithelial ovarian cancer","volume":"41","author":"Lee","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0060","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/RLU.0b013e31829f57fa","article-title":"Prognostic predictive value of total lesion glycolysis from 18F-FDG PET\/CT in post-surgical patients with epithelial ovarian cancer","volume":"38","author":"Liao","year":"2013","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0061","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.clon.2018.04.007","article-title":"Clinical value of 18 F-fluorodeoxyglucose positron emission tomography\/computed tomography in response evaluation after primary treatment of advanced epithelial ovarian cancer","volume":"30","author":"Hynninen","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0062","doi-asserted-by":"crossref","first-page":"vii218","DOI":"10.1093\/annonc\/mdq377","article-title":"Optimal treatment for relapsing ovarian cancer","volume":"21","author":"Ledermann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0063","unstructured":"Fehm T, Heller F, Kr\u00e4mer S, et al. Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 25:1551-1554."},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0064","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0090-8258(92)90254-G","article-title":"Long-term follow-up of ovarian cancer with monthly determinations of serum CA 125","volume":"46","author":"H\u00f6gberg","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0002-9378(86)90077-3","article-title":"The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer","volume":"155","author":"Niloff","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0066","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1200\/JCO.2005.02.2582","article-title":"Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 Levels within the normal range","volume":"23","author":"Santillan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0067","unstructured":"NCCN.org. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) ovarian cancer including fallopian tube cancer and primary peritoneal cancer version 4. 2017.; 2017."},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0068","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0069","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/wjnm.WJNM_31_17","article-title":"Systematic review on the accuracy of positron emission tomography\/computed tomography and positron emission tomography\/magnetic resonance imaging in the management of ovarian cancer: Is functional information really needed","volume":"16","author":"Suppiah","year":"2017","journal-title":"World J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0070","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1097\/RLU.0b013e31825b2583","article-title":"Revisiting the clinical value of 18F-FDG PET\/CT in detection of recurrent epithelial ovarian carcinomas: Correlation with histology, serum CA-125 assay, and conventional radiological modalities","volume":"37","author":"Antunovic","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0071","first-page":"175","article-title":"Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 Levels by 2-[F-18]Fluoro-2-Deoxy- d-Glucose-positron emission tomography\/computed tomography","volume":"26","author":"Peng","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0072","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00259-008-0776-3","article-title":"Performance of integrated FDG\u2013PET\/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: Comparison with integrated FDG\u2013PET\/non-contrast-enhanced CT and enhanced CT","volume":"35","author":"Kitajima","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0073","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00404-010-1568-0","article-title":"Impact of positron emission tomography\/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment","volume":"283","author":"Nasu","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0074","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MNM.0b013e32834fc5bf","article-title":"Diagnostic value of PET\/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer","volume":"33","author":"Sanli","year":"2012","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0075","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2014.02.008","article-title":"Utility of 18F-FDG PET\/CT in follow-up of patients with low-grade serous carcinoma of the ovary","volume":"133","author":"Takeuchi","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0076","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/MNM.0000000000000477","article-title":"Diagnostic performance of 18F-FDG PET\/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy","volume":"37","author":"Tawakol","year":"2016","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0077","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2006.10.060","article-title":"Clinical use of combined positron emission tomography and computed tomography (FDG-PET\/CT) in recurrent ovarian cancer","volume":"105","author":"Thrall","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0078","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00066-004-1208-3","article-title":"The influence of CA 125 and CEA levels on the results of (18)F-deoxyglucose positron emission tomography in suspected recurrence of epithelial ovarian cancer","volume":"180","author":"Menzel","year":"2004","journal-title":"Strahlenther Onkol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0079","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s00259-006-0306-0","article-title":"Integrated PET\/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer","volume":"34","author":"Mangili","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003072-900000000-97376","article-title":"The prognostic value of 18F-FDG PET\/CT in monitoring chemotherapy in ovarian cancer both at initial diagnosis and at recurrent disease","volume":"43","author":"Rubello","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0081","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00259-013-2610-9","article-title":"Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer","volume":"41","author":"Ebina","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0082","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ygyno.2006.03.004","article-title":"The impact of PET\/CT in the management of recurrent ovarian cancer","volume":"103","author":"Simcock","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0083","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3389\/fmed.2015.00046","article-title":"Clinical and survival impact of FDG PET in Patients with suspicion of recurrent ovarian cancer: A 6-Year follow-up","volume":"2","author":"Rusu","year":"2015","journal-title":"Front Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0084","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/gyno.2001.6386","article-title":"2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer","volume":"83","author":"Zimny","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cpet.2017.11.011","article-title":"Emerging molecular imaging techniques in gynecologic oncology","volume":"13","author":"Lin","year":"2018","journal-title":"PET Clin"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0086","first-page":"247","article-title":"Targeted \u03b1-therapy of prostate cancer using radiolabeled PSMA inhibitors: A game changer in nuclear medicine","volume":"8","author":"Chakravarty","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0087","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0088","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/ijms15010361","article-title":"Chemokine receptors in epithelial ovarian cancer","volume":"15","author":"Muralidhar","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0089","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/med.21473","article-title":"The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role","volume":"38","author":"Thuwajit","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13550-018-0442-0","article-title":"PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma","volume":"8","author":"Vag","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2019.06.010_bib0091","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.119.227967","article-title":"FAPI-PET\/CT: Mean intensity of tracer-uptake (SUV) in 28 different kinds of cancer","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299819300595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299819300595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:34:38Z","timestamp":1757543678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299819300595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0001299819300595"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.06.010","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT for Evaluation of Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2019.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}